Valence8 US LP Makes New $103,000 Investment in Vistagen Therapeutics, Inc. (NASDAQ:VTGN)

Valence8 US LP bought a new position in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 34,376 shares of the company’s stock, valued at approximately $103,000. Valence8 US LP owned about 0.13% of Vistagen Therapeutics at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of VTGN. Blair William & Co. IL lifted its holdings in Vistagen Therapeutics by 29.2% during the 2nd quarter. Blair William & Co. IL now owns 88,466 shares of the company’s stock worth $308,000 after buying an additional 20,000 shares in the last quarter. American Century Companies Inc. lifted its stake in shares of Vistagen Therapeutics by 49.1% during the second quarter. American Century Companies Inc. now owns 30,315 shares of the company’s stock valued at $105,000 after acquiring an additional 9,984 shares during the period. Finally, Acadian Asset Management LLC bought a new position in Vistagen Therapeutics in the first quarter valued at about $169,000. 78.39% of the stock is currently owned by institutional investors and hedge funds.

Vistagen Therapeutics Price Performance

Shares of NASDAQ VTGN opened at $2.54 on Friday. The company’s 50 day simple moving average is $2.99 and its 200 day simple moving average is $3.44. Vistagen Therapeutics, Inc. has a fifty-two week low of $2.52 and a fifty-two week high of $5.86. The firm has a market capitalization of $70.72 million, a P/E ratio of -2.05 and a beta of 0.78.

Analyst Ratings Changes

Separately, William Blair raised Vistagen Therapeutics to a “strong-buy” rating in a report on Friday, August 30th.

Vistagen Therapeutics Company Profile

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.